What's The Point Of Nobody Caring About Personalized Depression Treatment > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications are not effective for a lot of patients suffering from depression. The individual approach to treatment could be the solution.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into personalized micro-interventions for improving mental health. We analyzed the best-fitting personalized ML models to each person using Shapley values, in order to understand their characteristic predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

Depression is one of the world's leading causes of mental illness.1 However, only about half of those suffering from the condition receive treatment1. To improve the outcomes, healthcare professionals must be able to identify and treat patients with the highest likelihood of responding to certain treatments.

The treatment of depression can be personalized to help. Using sensors for mobile phones, an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from which treatments. Two grants worth more than $10 million will be used to discover the biological and behavioral predictors of response.

The majority of research conducted to the present has been focused on clinical and sociodemographic characteristics. These include demographics like gender, age and education, as well as clinical characteristics like symptom severity and comorbidities as well as biological markers.

Few studies have used longitudinal data in order to predict mood in individuals. Many studies do not take into consideration the fact that mood can vary significantly between individuals. Therefore, it is important to develop methods which allow for the analysis and measurement of individual differences between mood predictors, treatment refractory depression effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can detect various patterns of behavior and emotions that differ between individuals.

The team also created a machine-learning algorithm that can identify dynamic predictors of each person's mood for depression. The algorithm blends these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype was linked to CAT DI scores that are a psychometrically validated symptoms severity scale. However the correlation was not strong (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely across individuals.

Predictors of symptoms

Depression is among the world's leading causes of disability1 yet it is often untreated and not diagnosed. In addition, a lack of effective interventions and stigma associated with depressive disorders stop many from seeking treatment.

To assist in individualized treatment, it is crucial to identify predictors of symptoms. However, the current methods for predicting symptoms depend on the clinical interview which is not reliable and only detects a small number of symptoms that are associated with depression.2

Machine learning can be used to combine continuous digital behavioral phenotypes captured by smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing depression treatment nice Inventory, CAT-DI) together with other predictors of symptom severity could improve the accuracy of diagnosis and the effectiveness of treatment for depression. Digital phenotypes can provide continuous, high-resolution measurements. They also capture a variety of unique behaviors and activity patterns that are difficult to capture with interviews.

The study included University of California Los Angeles students with moderate to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online assistance or in-person clinics depending on their depression severity. Those with a CAT-DI score of 35 or 65 were allocated online support with the help of a peer coach. those with a score of 75 were routed to in-person clinics for psychotherapy.

Participants were asked a series of questions at the beginning of the study concerning their psychosocial and demographic characteristics as well as their socioeconomic status. The questions included age, sex and education and marital status, financial status, whether they were divorced or not, current suicidal ideas, intent or attempts, as well as how often they drank. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale of 100 to. The CAT-DI assessment was performed every two weeks for those who received online support, and weekly for those who received in-person care.

Predictors of the Reaction to Treatment

Research is focused on individualized depression treatment. Many studies are focused on identifying predictors, which will help doctors determine the most effective medications for each person. Pharmacogenetics, in particular, uncovers genetic variations that affect the way that our bodies process drugs. This allows doctors to select the medications that are most likely to work best for each patient, reducing the time and effort in trial-and-error procedures and eliminating any side effects that could otherwise slow progress.

Another promising method is to construct prediction models using multiple data sources, such as data from clinical studies and neural imaging data. These models can be used to determine the variables that are most predictive of a particular outcome, like whether a drug will improve mood or symptoms. These models can be used to determine a patient's response to an existing treatment and help doctors maximize the effectiveness of current therapy.

A new generation uses machine learning methods such as supervised and classification algorithms such as regularized logistic regression, and tree-based techniques to combine the effects from multiple variables to improve the accuracy of predictive. These models have been shown to be useful in predicting treatment outcomes for example, the response to antidepressants. These techniques are becoming increasingly popular in psychiatry, and are likely to become the standard of future treatment.

Research into the underlying causes of depression continues, in addition to predictive models based on ML. Recent findings suggest that the disorder is associated with dysfunctions in specific neural circuits. This theory suggests that individualized depression treatment will be built around targeted treatments that target these circuits to restore normal function.

Internet-based interventions are a way to achieve this. They can offer a more tailored and individualized experience for patients. For example, one study discovered that a web-based treatment was more effective than standard care in reducing symptoms and ensuring a better quality of life for people suffering from MDD. A randomized controlled study of a customized treatment for depression revealed that a substantial percentage of patients saw improvement over time and fewer side consequences.

Predictors of Side Effects

A major issue in personalizing depression treatment involves identifying and predicting the antidepressant medications that will have minimal or no side effects. Many patients experience a trial-and-error approach, with a variety of medications prescribed before finding one that is safe and effective. Pharmacogenetics provides an exciting new way to take an efficient and specific approach to selecting antidepressant treatments.

A variety of predictors are available to determine the best way to Treat depression antidepressant to prescribe, including genetic variants, phenotypes of patients (e.g. gender, sex or ethnicity) and the presence of comorbidities. However, identifying the most reliable and valid predictors for a particular treatment is likely to require randomized controlled trials of significantly larger numbers of participants than those typically enrolled in clinical trials. This is because it may be more difficult to detect interactions or moderators in trials that comprise only one episode per participant instead of multiple episodes spread over a period of time.

Furthermore the prediction of a patient's reaction to a particular medication will also likely require information about comorbidities and symptom profiles, as well as the patient's personal experience of its tolerability and effectiveness. Currently, only some easily measurable sociodemographic and clinical variables are believed to be reliable in predicting response to MDD like gender, age race/ethnicity BMI, the presence of alexithymia, and the severity of depression symptoms.

Many issues remain to be resolved in the application of pharmacogenetics to treat depression. First, it is essential to be able to comprehend and understand the definition of the genetic mechanisms that cause depression, as well as an understanding of a reliable indicator of the response to treatment. Ethics, such as privacy, and the responsible use of genetic information must also be considered. In the long run, pharmacogenetics may be a way to lessen the stigma that surrounds mental health treatment and improve treatment outcomes for those struggling with depression. However, as with any approach to psychiatry careful consideration and implementation is required. For now, it is recommended to provide patients with a variety of medications for antenatal depression treatment that work and encourage patients to openly talk with their doctors.